Tyzeka

Schinazi, R

Tyzeka™ is the trade name for telbivudine, a synthetic thymidine nucleoside analogue with activity againsta hepatitis B virus (HBV) and is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Tyzeka/Sebivo was co-developed by Idenix Pharmaceuticals, Inc. and Novartis Pharma AG. Novartis Pharma AG has exclusive worldwide commercialization rights to Tyzeka/Sebivo